金融毒性瘤委员会:五年实践更新和实施指南
Thomas G Knight1, Caitlin Hensel1, Kris Blackley1
1Levine Cancer Institute, Atrium Health, Charlotte, NC.
Journal of the National Comprehensive Cancer Network : JNCCN
|April 16, 2025
概括
金融毒性瘤委员会 (FTTB) 通过机构级干预措施,成功地减少了癌症患者的金融毒性. 这种创新模式结合了多学科委员会和患者援助计划,提供了新的护理标准.
科学领域:
- 在瘤学瘤学.
- 医疗保健服务研究 医疗服务研究
- 卫生经济学 卫生经济学
背景情况:
- 财务毒性是癌症治疗结果的重要障碍.
- 以前的干预主要集中在个人患者的支持上.
- 金融毒性瘤委员会 (FTTB) 是首个针对癌症相关财务困境的机构级干预机构.
研究的目的:
- 报告五年来FTTB的功能和成果.
- 评估机构层面干预措施在缓解金融毒性的有效性.
主要方法:
- 该FTTB作为一个多学科的瘤董事会,解决财务困境.
- 演变为以疾病为中心的会议和用于病例分类的原型系统.
- 扩大以药房为基础的患者援助计划 (PAP),以支付更广泛的癌症护理费用.
主要成果:
- 向瘤委员会提交的70多个病例导致了立即的患者解决方案和系统变化.
- 在FTTB的PAP提供了超过1030万美元的共同支付援助9,321名患者.
- 价值超过3.92亿美元的免费药物分发给了16.495名患者.
结论:
- FTTB模型表明,系统干预显著改善了金融毒性.
- 瘤委员会和PAP部门在患者的财务状况方面取得了重大改善.
- FTTB模型代表了在瘤学中管理金融毒性的潜在新护理标准.
相关概念视频
Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Standards of Care II
Nurses bear specific legal responsibilities under several federal statutes, including:
Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...


